| Literature DB >> 26543432 |
Kathleen F McGinley, Gregory C McMahon1, Gordon A Brown.
Abstract
On October 7, 2011, the United States Preventive Services Task Force (USPSTF) released their evidence statement and grade D recommendation against prostate-specific antigen (PSA)-based prostate cancer screening. Using a time series design, we assessed the effect of this recommendation upon evaluations for elevated PSA levels and prostate biopsies in our large urology group practice. We found that, despite a 24.1% increase in total visits, the 32 urologists in our practice completed 16.4% fewer evaluations for elevated PSA levels (317 fewer evaluations per month; P = .017) and 21.4% fewer prostate biopsies (42 fewer biopsies per month; P = .001) in the 2 years following the USPSTF grade D recommendation.Entities:
Keywords: Prostate biopsies; Prostate cancer screening; Prostate-specific antigen; United States
Year: 2015 PMID: 26543432 PMCID: PMC4633661
Source DB: PubMed Journal: Rev Urol ISSN: 1523-6161